Global
Global Plants
Daewoong Pharmaceutical has a number of strategically located manufacturing sites, each of which specializes in various production lines such as depot, liquid suspension, biologics, and etc.
Osong Plant
Chungcheongbuk-do, South Korea
Feature
- Highly automated mass production facility
- Qualified injection manufacturing facility
Depot injection & ampoule, vial, drip infusion kit
First in Korea to be equipped with Dual Chamber
- Syringe (DCS) charging line)
- Capacity: Dual Chamber Syringe (0.35M), Prefilled Syringe (0.25M), Tablet (2B)
Area
40,892 m² (440,158 ft²)
Manufacturing
Products
Oral Solid, Depot Injection, Vial, Ampoule
Hyangnam
Plant
Hyangnam, South Korea
Feature
- Main manufacturing site for oral solids, suspensions, injectables and biologics
- Produces Korea’s first new biomedicine ‘EGF’ (Epidermal Growth Factor)
- Supports clinical trial(phase 1-3) batch sizes and clinical scale-up manufacturing
- Capacity: Tablet (1B), Prefilled Syringe (1M)
Area
31,735 m² (341,598 ft²)
Manufacturing
Products
Oral Solid, Microbial Product, Cell cultured Product
Seongnam
Daewoong-Bio
Plant
Seongnam, South Korea
Feature
- Top cephalosporin CMO facility
- RABS (Restricted-access barrier system) ensures sterility and validated aseptic-quality products
- Capacity: Powder Injection Filling Line (24M Vial), Tablet (100M), Capsule (100M)
Area
7,535 m² (81,106 ft²)
Manufacturing
Products
Cephalosporin Injection, Tablet, Capsule
Anseong
Daewoong-Bio
Plant
Anseong, South Korea
Area
8,180 m² (88,048 ft²)
Manufacturing
Products
Oral Solid
Daejeon Plant
(HANALL BIOPHARMA)
Daejeon, South Korea
Area
9,011 m² (96,993 ft²)
Manufacturing
Products
A/A infusion, Oral Solid
ChinaLiaoning Plant
Liaoning
Feature
- Closed system throughout the production process
- BIN System based transfer and handling
- Unmanned ingredient transfer using line and pump
- Capacity: Oral Liquid (200M pouch, 30M bottle)
Area
9,586 m² (103,182 ft²)
Manufacturing
Products
Liquid for oral administration
ChinaSichuan Plant
Sichuan
Feature
- Top gall bladder-related production technology
- UDCA intermediate production
- API & CDCA (Chenodeoxycholic acid)
Area
10,000 m² (81,106 ft²)
Manufacturing
Products
Chenodeoxycholic acid, crude Cholic acid
Total Capacity
per Year
| Type | Quantity |
|---|---|
| Tablet | 6.7 Billion |
| Capsule | 205 Million |
| Vial | 70 Million |
| Bottle | 102 Million |
| Pouch | 130 Million |
| Syringe | 5.6 Million |
| Bag | 0.5 Million |
| Ampoule | 0.1 Billion |
| Kit | 7 Million |